Showing results (111-120 of 223) with videos related to
Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2022
The Critical Role of Academic Clinical Trials in Pediatric Cancer Drug Approvals: Design, Conduct, and Fit for Purpose Data for Positive Regulatory DecisionsBram De Wilde, Elly Barry, Elizabeth Fox, et al.Pediatric Blood & Cancer|October 16, 2019
The ganglioside GD2 as a circulating tumor biomarker for neuroblastomaFrank Milton Balis, Christine Maria Busch, Ami Vijay Desai, et al.The Lancet. Oncology|April 20, 2013
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium studyYael P Mossé, Megan S Lim, Stephan D Voss, et al.Pediatric Blood & Cancer|April 21, 2021
A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515)Thomas Cash, Elizabeth Fox, Xiaowei Liu, et al.The New England Journal of Medicine|August 6, 2004
Loss of Smad3 in acute T-cell lymphoblastic leukemiaLawrence A Wolfraim, Tania M Fernandez, Mizuko Mamura, et al.Cancer|September 9, 2017
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trialsWendy B London, Rochelle Bagatell, Brenda J Weigel, et al.Journal of Neuro-Oncology|October 5, 2011
A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium studyKatherine E Warren, Sri Gururangan, J Russell Geyer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2020
Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory SettingNavid Hafez, Hope S Rugo, Margaret A Tempero, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2018
New Agents, Emerging Late Effects, and the Development of Precision SurvivorshipEric J Chow, Zoltan Antal, Louis S Constine, et al.Pediatric Blood & Cancer|June 26, 2014
Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumorsRobin E Norris, Suzanne Shusterman, Lia Gore, et al.Pageof 23